An intragastric balloon produced significant weight loss without triggering the compensatory rise in appetite hormones that typically promotes weight regain after dieting.
No compensatory ghrelin rise at 12 monthsUnlike typical diet-induced weight loss, neither the balloon group nor the diet-only group showed the hormonal rebound that usually promotes weight regain.
What the researchers found
Weight loss achieved with an intragastric balloon did not alter fasting levels of peptide YY (PYY) or adiponectin. Ghrelin increased while the balloon was in place (+39.3 pmol/L vs. baseline) but returned to baseline after removal (-34.7 pmol/L). Leptin decreased at 6 months (-11.7 ng/mL) but rebounded to baseline after balloon removal. Critically, no compensatory rise in ghrelin was observed in either group 12 months after initial weight loss, suggesting that this approach may avoid the hormonal rebound that typically drives weight regain after dieting.
Why it matters
One of the biggest challenges in weight loss is that the body's appetite hormones shift to promote weight regain. This study suggests that intragastric balloon-assisted weight loss may not trigger the same unfavorable hormonal changes seen with diet alone — particularly the feared compensatory ghrelin surge. Understanding how different weight loss methods affect appetite-regulating peptides is essential for developing strategies that produce lasting results.
The numbers in context
n=66 · ghrelin +39.3 pmol/L during IGB · ghrelin -34.7 pmol/L after removal · leptin -11.7 ng/mL at 6 months · 12-month follow-up · no compensatory ghrelin rise at 12 months
How the study worked
Sixty-six obese adults with metabolic syndrome were randomized into two groups: one received an intragastric balloon for 6 months combined with a 12-month behavioral modification program, while the other received the behavioral program alone. Anthropometric measurements and blood samples were collected every 3 months. Fasting levels of ghrelin, peptide YY, adiponectin, and leptin were measured throughout the study period.
Who was studied
Obese adults with metabolic syndrome
What this study cannot tell us
The study measured only fasting hormone levels, which may not capture the full postprandial hormonal response. The sample size of 66 participants is moderate. The follow-up period was 12 months, so longer-term hormonal changes remain unknown. The study focused on metabolic syndrome patients, so findings may not generalize to all obese populations.
How to read the evidence
This is a randomized controlled trial with 66 participants and a 12-month follow-up, providing moderate-quality evidence. The randomized design strengthens causal inference, though the moderate sample size and single-center design are limitations.
When this study was published
Published in 2013, this study is over a decade old. While the hormonal mechanisms studied remain relevant, newer research on GLP-1 receptor agonists and other peptide-based treatments has since expanded the obesity treatment landscape significantly.
The bigger picture
This study contributes to our understanding of how appetite-regulating peptides respond to different weight loss interventions. The finding that intragastric balloon treatment does not provoke a compensatory ghrelin surge is encouraging for the field of obesity management, as hormonal rebound is considered a major driver of weight regain. It also highlights the complex interplay between mechanical satiety interventions and the neuroendocrine systems that peptides like ghrelin, PYY, and leptin are part of.
Questions still open
- Would measuring postprandial (rather than just fasting) peptide levels reveal different hormonal responses to intragastric balloon treatment?
- Does the absence of compensatory ghrelin rise persist beyond 12 months, and does this translate into better long-term weight maintenance?
- Could combining intragastric balloon treatment with peptide-based therapies (like GLP-1 agonists) produce synergistic weight loss effects?
Common questions
Why is it significant that ghrelin didn't rise after weight loss?
What is the difference between how the balloon group and diet group affected appetite hormones?
Read the original research
An intragastric balloon produces large weight losses in the absence of a change in ghrelin or peptide YY.
Clinical obesity, 3(6), 172-9
Citation
Fuller, N R; Lau, N S; Denyer, G; Caterson, I D. (2013). An intragastric balloon produces large weight losses in the absence of a change in ghrelin or peptide YY.. Clinical obesity, 3(6), 172-9. https://doi.org/10.1111/cob.12030